The Story Of Our Firm | En Español
 Home    Lawyers   Litigation   Choose Us   Settlements   Search
FONT SIZE: A A A A A

Previous Investigations Other Litigations Bextra Research Center News & Warnings Drug Publications

New Bextra Label Updates

in this section: Public Health Advisory NSAID Products | FDA Recommends Limiting Use of Cox-2 Inhibitors | Bextra Warning Letter on Skin | New Bextra Label Updates

Bookmark This Page Print This Page Email This Page

November 15, 2002

FDA, PHARMACIA UPDATE BEXTRA LABEL WITH NEW WARNINGS

FDA and Pharmacia are advising health care professionals about new warnings and information in the product labeling of the drug Bextra (valdecoxib), a drug approved for treatment of osteoarthritis, rheumatoid arthritis and dysmenorrhea (menstrual pain). The labeling is being updated with new warnings following postmarketing reports of serious adverse effects including life-threatening risks related to skin reactions -- including Stevens Johnson Syndrome, and anaphylactoid reactions (serious allergic reactions). In addition, the labeling will state that the drug is contraindicated -- not to be used -- in patients allergic to sulfa containing products.

On November 13, 2002, Pharmacia, the manufacturer of Bextra sent letters to health care professionals advising them of postmarketing reports and new warnings that will be included in the drug label. Since the firm began marketing the drug in March of 2002, cases of the serious skin and hypersensitivity reactions have been reported. These included cases of Stevens Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis and erythema multiforme. Although these adverse events are rare, some of these patients required hospitalization. Based on these reports, FDA has approved labeling changes for Bextra that include a warning for serious skin reactions. As these reactions can be life threatening, people who start Bextra and experience a rash should discontinue the drug immediately.

Weitz & Luxenberg is no longer accepting Bextra cases.


see also:

Public Health Advisory NSAID Products Cox-2 inhibitor Litigation - Vioxx, Bextra, Celebrex Lawers - FDA Public Health Advisory
Public Health Advisory Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS)

Bextra Warning Letter on Skin Bextra Litigation - Bextra Lawyers - Bextra Warning Letter on Skin Reactions
On November 1, 2002, the department of health and human services officially warned Pharmacia of the dangerous skin related side effects of its drug Bextra. Here is the official warning.

Warnings Bextra Attorney - Bextra Warnings
Injured by Bextra? Your doctor can help, then contact your Bextra Attorney
Free Legal Review
Name:
Phone:
Email:
Case Description:
$53 million verdict — brake mechanic suffering from mesothelioma

$13.5 million verdict — one of the very first Vioxx trial cases

$15 million settlement — man wound up a paraplegic due to negligent hospital care

$37 million verdict — 2 asbestos lung cancer plaintiffs

$47 million verdict — boilermaker who died from mesothelioma

$2.6 million settlement — ill-fitting prosthesis caused decubitus ulcers

$75 million verdict — historic consolidated trial involving men who had worked at the Brooklyn Navy Yard in the 1940s and 1950s

$12.7 million verdict — iron worker who was injured due to unsafe working conditions

$8 million settlement — obstetrical malpractice resulted in neurological deficits

$64.65 million award — 4 asbestos plaintiffs

$17.5 million — consolidated trial of 5 mesothelioma victims


Ask a Free Question:
Were you injured?

check for your response [login]
For legal help anywhere in the U.S.
A nationally-recognized personal injury law firm, Weitz & Luxenberg is committed to helping clients win cases, get the compensation to which they’re entitled and continue with their lives. In just over 20 years, we’ve collected more than $1.3 billion for plaintiffs.